Inmune Bio INMB
NASDAQ INMB
$1.61 +0.01 (+0.62%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inmune Bio (INMB) EBITDA (2025 - 2026)

Updated

Inmune Bio's EBITDA came in at -$1.38 million for Q2 2026.

Analysis

Inmune Bio (INMB) EBITDA (2025 - 2026) Analysis & Trends

For FY2025, Inmune Bio's EBITDA was -$47.3 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 12.29 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 9.10 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 8.33 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 999.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 5.09 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 4.63 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -9.70 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 5.89 Bn
10 Inmune Bio 42.88 Mn -49.37 Mn - -1.38 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.38 Mn
Mar 31, 2026 -5.76 Mn
Dec 31, 2025 -5.42 Mn
API Access

Inmune Bio EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=INMB&period=max&api_key=YOUR_API_KEY